Hims & Hers Health, Inc. (HIMS) Earnings Call Transcript
May 11, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and welcome to Hims & Hers Health's first quarter 2026 earnings call. Before we get started, I'd like to share an update regarding how we handle earnings communications. Going forward, the company is moving to an annual shareholder letter, and we will keep providing regular updates via a quarterly earnings call, earnings release, and supplemental materials; our belief is that this approach lets our shareholder letter capture the long-term character of our strategy and highlight the sustained value we are building. Joining me on the call today are Andrew Dudum, our Co-Founder and Chief Executive Officer, Yemi Okupe, our Chief Financial Officer, and Mo Elshenawy, our Chief Technology Officer. Before turning things over to Andrew, I must remind you about legal safe harbor and cautionary declarations. A number of statements and projections of future results included in this presentation are forward-looking statements, which rest on, among other things, our current market, competitors, and regulatory expectations, and which carry risks and uncertainties that might cause actual results to differ materially. We assume no obligation to publicly update any forward-looking statement following this call, whether due to new information, future events, changes in assumptions, or otherwise. The risks, uncertainties, and other factors that might cause actual results to differ from our forward-looking statements are set out in our earnings release and SEC filings. Please review our recent earnings release and our most recently filed 10-K and 10-Q reports for a discussion of these risk factors as they relate to forward-looking statements. In today's presentation, we also include certain non-GAAP financial measures. We point you to the reconciliation tables to the most directly comparable GAAP financial measures contained in today's press release. You can find this information, along with a link to today's webcast, at investors.hims.com. Following the call, this webcast will remain archived on the website for 12 months; with that, I'll hand the call over to Andrew.
Thanks, Bill. Good afternoon, everyone, and thanks for being here. At Hims & Hers, this has been a powerful and significant opening to the year; we've achieved meaningful advances on the strategic goals we think will shape our platform over the coming 10 years. Notably, 2026 is turning out to be a period of speeding-up expansion, which strengthens our conviction in our bold 2030 objectives. Before Yemi walks us through our results, I'd like to call out several important areas that illustrate our advances. First, our business in the U.S. is set up to speed up as we roll out new specialties and move our weight loss approach toward one that is unified globally. Second, our worldwide footprint is fast turning into a competitive edge, not just because it widens our TAM, but because it grows our value to industry partners and boosts the network effects of our platform. Third, we're making our customer ties stronger while addressing genuine, agonizing shortfalls in the conventional care system through an offering that is more proactive. This means we're opening up the possibility of relationships with our customers that last longer. Fourth, ongoing spending on our data and technology backbone is producing a platform that is increasingly nimble and grows smarter with each additional customer. With tens of millions of customer touch points each year and a provider network that is closed-loop, we're gathering a potent data set that is getting tougher to copy. These investments are unlocking faster, more efficient growth geographically and in products, interactions with customers that are more valuable, and engagement with our platform that is deeper. On that foundation, Hims & Hers is progressing toward becoming an everyday health partner, not only for the nearly 2.6 million people we serve right now, but for millions more across the globe. Let's begin with the building momentum we're seeing in the U.S. The range of care we're able to deliver is turning into a genuine strategic edge, giving customers additional ways to begin with Hims & Hers and additional reasons to remain with us as time goes on. We see momentum in newer specialties such as testosterone, menopause, and labs, and our growing lineup of branded GLP-1 solutions is fueling accelerating momentum in our weight loss business. The count of people we can assist has never been bigger or more varied, and we're working to make sure they can access the widest possible range of treatment options; in weight alone, over 100 million adults in the U.S. are struggling. Demand for treatments that work and are accessible keeps rising, and the market is changing quickly to satisfy this need with more form factors and prices that are lower. In March, we announced a strategic shift in our weight loss business that acknowledges this evolution and concentrates on giving customers on our platform access to the widest possible assortment of innovative medications. Together with a comprehensive experience that includes access to the data-driven clinical care and lifestyle support our customers have come to expect. Platforms like ours are the place pharma, biotech, and diagnostic companies are increasingly relying on to reach more people with innovative treatments and services. Take our work with Novo Nordisk as an illustration. It demonstrates what can happen when companies innovating in health join forces, aiming to help a greater number of individuals feel terrific. Adoption and weight reduction are currently at levels close to records, surpassing even the demand generated by this year's New Year's and Super Bowl campaigns. Just 6 weeks after we began offering direct access to Novo Nordisk's GLP-1 products on our platform, we've completed fulfillment of over 125,000 shipments of Wegovy products. The Wegovy Pill, in particular, has our customers enthusiastic. Their reaction to the affordable price, the impressive efficacy, and the strong safety profile has been extremely positive; clearly, it's a powerful blend of efficacy, safety, and affordability. Novo has been a wonderful partner to us, and I'm eager to look into additional ways we could work together going forward. Last month, we also shared that providers using our platform may now transmit prescriptions for Zepbound vials and KwikPen, plus Sonder, to the LillyDirect pharmacy, and obtain self-pay pricing for Hims & Hers customers. Our capacity to build awareness and cultural discussions around accessibility, together with our investment in a deeply personal, continuous experience, gives our partners confidence that those we help them reach are receiving access to excellent care and are more inclined to stay engaged as time goes on. Turning to the second area fueling our progress: our expanding global scale. We are quickly turning into the world's biggest consumer health platform, which amplifies our impact. We anticipate our planned acquisition of Eucalyptus will close during the second half of this year. This will broaden our leadership position in consumer health throughout Australia, the U.K., Germany, Japan, and Canada by using local expertise and established industry relationships. As we reinforce our footprint in current and new regions, we have the chance to touch hundreds of millions of people, drawing more data points into our ecosystem and extending our platform's network effects around the world. Getting customers onto the platform is merely the initial step. We're assisting customers in establishing a long-term daily health routine that they feel driven to keep up, converting improved access and broader treatment choices into better health and forging relationships we believe can endure for decades; we view ourselves as the top global platform for our industry partners for 2 reasons. First, our worldwide reach lets us fuel category growth in new and existing markets. Second, by delivering a high-touch, personalized experience, our platform is built to help customers remain on their treatment plans longer and achieve their goals better than with medication alone. That brings me to the third area of progress I want to emphasize. As we expand, we are turning into more than simply a place for anyone seeking to manage existing conditions. We are a trusted, all-encompassing health partner that assists customers in proactively spotting early signs of conditions that might not yet be symptomatic. Our testosterone product is performing strongly and currently helps tens of thousands of men, which illustrates this point perfectly. For a lot of men, indicators that testosterone is low get dismissed as mere fatigue or simply a natural part of aging. That shifts with Hims. We built this offering to identify a significant problem that most men cannot perceive until it grows hard to disregard. Through straightforward at-home blood tests, customers are able to monitor their testosterone levels across time, collaborate with the providers to figure out which treatment suits them, and then readily tweak that treatment when appropriate according to their newest blood test. We observe that this type of proactive connection and effortless at-home experience generates genuine outcomes for customers. Among Hims customers who depend on us for this testosterone support, 95% experienced a rise in testosterone levels inside two months. By favoring investments that strengthen our customer relationships, we make it easier for anyone to take a more proactive approach to feeling their best. Our belief is that investing in YourBio's microneedle blood sampling technology will allow deeper health insights across key biomarkers to become even simpler to obtain via a quick, painless blood draw. Rather than waiting for symptoms such as cardiovascular risk, sexual dysfunction, or hormone imbalance to show up, customers may obtain a complete view of their present health and address particular risk factors before those factors become conditions that affect their everyday life. That information layer is going to be essential in backing new specialties such as testosterone and menopause as they grow. Even more importantly, it enables our platform to develop alongside our customers as their needs shift. Increasingly, we notice customers seeking genuinely proactive and continuous care, guided by health insights that assist them not merely in getting healthy, but in staying healthy. This is fundamental to the way the Hims & Hers customer experience gets better over time. That leads me to the fourth area of progress I wish to emphasize. We are constructing a health platform that provides access to higher quality care as we grow, and that is growing more difficult to copy. I want to ask Mo Elshenawy, our CTO, to discuss further the progress his team has achieved and the customer experience they are delivering. Considering how fast our technology infrastructure is growing and the enormous effect we anticipate it will have on the business's future, we are delighted to have Mo with us every quarter.
Thanks, Andrew. It's great to be here again and talk about the way we're using data and AI so that we become a companion our customers can't do without, plus an extremely valuable partner for other health innovators eager to reach and retain more customers. Before I turn to the platform, I'd like to give you an update on the team. We run a small engineering group that's exceptionally talented, and it's led by senior people who are still writing code daily; on top of that, we built our AI organization from nothing; at this point we have close to 40 people on the AI team, among them senior AI engineers and applied scientists, PhDs out of MIT, Berkeley, and other leading schools, plus experienced leaders who came from major tech companies. Leaders of that caliber are picking Hims & Hers because they see the same things we do. A platform with the scale, data, infrastructure, and customer trust needed to take advantage of today's technological progress and change what people think is achievable in healthcare. At this moment, our teams have their attention fixed on three main priorities. To start, we're advancing the existing operating system so that it delivers stronger support to both our customers and providers throughout the full continuum of care, rather than addressing a single condition in isolation. For the coming stage of our expansion, we need a platform that can manage more intricate demands while simultaneously becoming easier to navigate for customers and providers alike. During the past year, we've been rebuilding that platform to center on modular, reusable components. Our technology stack is built to expand smoothly into additional conditions, categories, and geographies, enabling us to introduce new products at an even quicker pace. Right now, what we've built includes a brand-new commercial engine that doesn't require code, clinical workflows you can easily configure, a refreshed experience for mobile and messaging, and a more complete picture of each customer's entire health journey. We're already seeing the payoff. Testosterone, menopause, and labs are initial examples showing our platform can help us move faster into additional parts of healthcare. This self-serve system supports adaptable pricing, promotions, membership options, and various treatment plans that can be tuned to drive better customer results — it's the base that allows us to reach more people across more conditions with greater efficiency. And second, we've placed intelligence throughout every stage of the care journey, while independent providers stay accountable for all clinical decisions. To give you one instance, there's an AI copilot we've already put into production on the provider side of things, and what it does is generate context-aware replies for our care coaches, who look them over prior to sending anything out. The point here isn't merely doing things faster — it's about raising the standard of care, since the replies draw on the complete picture of each patient, something human coaches by themselves couldn't manage at that volume. Another recent introduction from us is Labs AI, an agent that interprets biomarker findings within each individual customer's own distinct circumstances, points out the things that deserve attention, and recognizes the right moment to suggest bringing in a provider. In the near future, we're rolling out an AI-driven weight loss companion designed to walk alongside customers throughout their journey, proactively making contact at the optimal moments to help them reach the outcomes they want, and calling in clinician involvement whenever that expertise becomes necessary. What ties all these tools together is that guardrails and evaluation frameworks sit right inside the architecture. Every AI-enabled workflow gets built with explicit boundaries around what it can manage on its own and what ought to be routed upward. At present, we handle tens of millions of customer touch points each year, and independent providers review, correct, and approve the AI inputs that shape our platform design. What that gives us is training data for our models that clinicians have actually checked over. You won't find a better label than that anywhere in AI, and there's no way to purchase it. Next, now that this infrastructure exists, we're strengthening a proprietary data flywheel that runs as a closed loop — something competitors simply can't copy. In the healthcare platform space, we're among a tiny handful where the consumer's initial visit and diagnosis, the path of treatment, the choices providers make, and the final results all live inside one unified stack. We designed our platform so it keeps getting better as that body of insight grows. Rather than seeking a second opinion, we aim to deliver the value of a 1,000th opinion straight into the Hims & Hers experience, guided by nine years of learning what works across a full spectrum of customer profiles. Each patient interaction teaches our model more about the range of possible experiences and needs. Each provider decision hones our clinical training data. Each outcome grows our evidence base, shedding light on what works, for whom, and why. Down the road, we intend to add support for wearables and devices, giving even deeper insight into our customers' everyday health. Higher-quality data kicks off a loop: it fuels more capable agents, leads to better care, draws elite providers into our networks, and keeps sharpening our clinical knowledge. Our worldwide footprint, we think, will work as an amplifier—models that mirror the populations, disease profiles, and care patterns across many regions will make the intelligence we're developing fundamentally stronger. The foundational IP that turns this experience into reality belongs to us. Our real differentiator lies in how we bring together providers, protocols, and regulatory frameworks, producing one cohesive care model that sets us apart from standard LLMs or cutting-edge AI labs. What sets us apart is that we handle the whole experience from start to finish, from the moment someone has a need all the way to a result, across every stage of a patient's path — symptoms, diagnosis, treatment, titration, side effects, and outcomes. We also see how these areas link together across different categories. From where we sit, combining this approach with our worldwide footprint gives us something no competitor has right now. The thing we're creating is a platform whose care categories keep growing, backed by an intelligence layer that tailors each part of the customer's journey, plus a trust framework that gives us the standing to operate in healthcare — which is why we think we're turning into the go-to platform for customers and partners throughout the ecosystem. We're not talking about something way off in the future here — this is going out the door right now. Appreciate it. Over to you, Andrew.
Thank you, Mo. Let me also mention that everything we're doing here won't merely drive richer insights and closer ties within the categories we already serve; we're convinced it will likewise serve as the foundation for moving into new areas such as peptides, using an intake process that is clinically rigorous and full of information, built to protect customers and keep providers properly educated. Several peptide therapies strike our medical team as having real promise, and it's encouraging to watch the FDA take steps toward spelling out more clearly what can be considered safe and permitted in this space. The companies that set the bar in this emerging category will be those that put the physician at the center of the experience, operate transparently, and stay fixated on getting customers good outcomes; nothing like that exists in the gray market of today, where the sole peptide choices are unregulated, vary in quality, and seldom come with any clinical backing. When it comes to this category, we'd take a different path — one centered on physician guidance and supervision, a dedication to pushing forward clinical knowledge regarding safety and efficacy, and providing access to treatments of high quality. Thanks to our verticalized infrastructure and supply chain within the country — which we bolstered by putting money into our own peptide facility located in the U.S. last year — we're confident customers can rely on us to deliver the same exacting standard for peptide therapies that they've come to expect from us in other categories. To put it more plainly, we will hold off on opening up access to peptides until we satisfy these exceptionally high benchmarks that, in our view, ought to be met by everyone. Let me close by noting that my confidence in our work of building the future of health has never been greater. With 9 years of data, a verticalized domestic supply chain, a nimble and smart platform, a top-tier global presence, and an expanding network of trusted health innovators, we hold clear advantages, and this strengthens our conviction in our 2030 goals of at least $6.5 billion in revenue along with $1.3 billion in adjusted EBITDA. We're reshaping the way care gets accessed worldwide, turning into the global destination that people rely on to feel their best daily. Through our platform, customers uncover a holistic, data-driven experience crafted around their real lives rather than some one-size-fits-all system. We're expanding what people think can be done. Health that's simple, profoundly personal, and made for daily living. Now I'll hand things over to Yemi, who will take you through the financials.
Thanks, Andrew. Back in March, we chose to make a purposeful strategic shift in our weight loss specialty, and we recognized at the time that it would generate some short-term financial turbulence in exchange for unlocking enormous potential for the platform to scale quickly. Today, I want to take you through what that decision has produced so far, the early proof that gives us confidence it was correct, where we plan to direct investment going forward, and lastly, how our financial picture develops from this point. We hold the view that the change we undertook — putting branded products first in our weight loss specialty — will prove transformational for the Hims & Hers platform, and we are already seeing signals of early success. As we have said before, the strength of our model comes from offering the best assortment of products alongside the powerful experience our platform delivers. In March, we stopped advertising compounding products so we could focus on growing the population we serve. With branded products now introduced, including the Wegovy Pill and Wegovy Pen, our addressable market is already expanding substantially. Just weeks after this launch, we are poised to bring on more than 100,000 new subscribers each month in our weight loss specialty. Initial indicators show strong subscriber involvement, with close to 90% of these users downloading the app, and the typical subscriber for these products engaging with the provider 3 x during month one. We see weight loss as a vital specialty because it can draw a wide audience of consumers onto the platform, which lets us cross-sell other products later on, gain scale across our pharmacies to speed up achieving economies of scale, and collect rich insights that improve data model quality and ultimately let us upgrade the tools and services we offer subscribers and providers. Our goal is to become the default health and wellness platform for consumers globally. In the near term, success means growing the addressable market and becoming a top health and wellness service provider in each of our key markets, all while preserving our capacity to generate healthy free cash flow. Over the longer term, we anticipate continuing to refine our cost structure and the value we deliver to consumers so that margins expand progressively. The strong early signals from our pivot, the continued solid execution by our team, and the growing size of the opportunity ahead of us all strengthen our confidence in hitting our 2030 ambitions: at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Our financial focus will be on speeding up growth to secure a leadership position in the U.S. and international markets, while keeping the discipline needed to ensure we keep generating healthy free cash flow. To achieve our longer-term aspirations, we are going through what will likely be a transitional period that could introduce volatility in GAAP results and ratios, as our first quarter results show. In the first quarter, revenue rose 4% year-over-year to $608 million. Our subscriber base expanded by 9% compared to the same period last year, reaching just under 2.6 million, while adjusted EBITDA came in at $44 million — a 7% adjusted EBITDA margin. In U.S. operations, both revenue and adjusted EBITDA faced temporary pressure from revenue recognition dynamics tied to shorter shipping cadences, made worse by a tougher comparable period stemming from record-level additions of weight-loss subscribers during last year's first quarter. International growth, fueled by our ZAVA and Livewell acquisitions, stayed robust, with revenue climbing almost tenfold versus the first quarter to hit $78 million. Our weight-loss specialty's strategic pivot weighed on the financials in the first quarter. Before that strategic pivot, we had invested meaningfully in product, technology, and other capabilities to support our GLP-1 compounding supply chain. Because of the pivot, we took on roughly $33 million in restructuring costs, mostly write-downs tied to our compounded GLP-1 supply chain, which now faces obsolescence risk. One-time charges of about $28 million dragged gross margins down by around five points in the first quarter, which came in at 65% on a GAAP basis and 70% once those costs are adjusted out. The other $5 million in one-time restructuring charges hit operations and support costs. During the first quarter, we kept investing in talent and capabilities across multiple areas, including technology and operations. We anticipate continued technology investment in the near term as the benefits ripple through various parts of the platform. Stronger infrastructure speeds up how quickly we can deliver new features and offerings to our consumers. On top of that, specialized technology and engineering talent puts us in position to unlock even greater value for our subscribers as we make better use of insights gathered throughout the consumer journey. What symptoms they had, which treatments helped and which did not, and what behavioral patterns drove better outcomes across different demographics. Such insights can increase tenure on the platform. Finally, AI talent specifically holds the potential to lower both organizational and operational costs in a manner that enhances rather than sacrifices service quality for subscribers; we anticipate technology investments will be financially accretive over the mid to long term, with ongoing signs of success showing up in the near term. We also expect continued near-term investment in our operational capabilities, which allow us to expand into new specialties and bring down our costs to serve subscribers over time. In the first quarter, we kept investing in talent so the organization is equipped to expand into more complex offerings like injectable-based low testosterone treatments; beyond that, we invested in talent to ensure we are well-positioned to seize opportunities for new offerings such as peptides as the regulatory landscape evolves. Trust remains the cornerstone of the Hims & Hers brand today and will continue to be as we scale. Just like before, any new specialty offering we add will be rolled out under a careful compliance-first, consumer-focused approach, so that the quality and safety of what we provide match the standards people have grown to expect from Hims & Hers. Because our marketing has become more efficient, we now have the freedom to put capital into these areas in a deliberate way. In Q1, marketing came in at 36% of revenue, which is a three-point gain both versus a year ago and versus the prior quarter. The improvements in efficiency trace back to better retention, more cross-selling that occurs naturally on the platform, and customers arriving through cheaper channels as our brand keeps building awareness. Our view is that as we keep widening the range of products offered on the platform, these efficiency gains can carry on, though there will be some fluctuation from one quarter to the next. Before I get into how we're investing, let me briefly restate what our operational priorities are. On the financial side, our main goal will be to keep growing the business while also making sure we produce robust free cash flow, so we can act fast when market opportunities appear. At times, that could mean investing more heavily or even making strategic shifts now and then that affect our GAAP financials, which is what happened in the first quarter. GAAP net income fell to a loss of $92 million in Q1.
The first quarter's results took a hit from several items: restructuring charges that won't repeat, tied to the strategic pivot in our weight loss specialty; deal-related transaction costs from M&A activity; and legal expenses. We do anticipate being in a position to get back to net income profitability in 2027, but driving strong growth and generating cash flow will be where our main attention goes. During Q1, cash flow from operations came to $89 million, and free cash flow was $53 million; we identified thoughtful ways to put capital to work on capabilities we're highly confident will fuel long-term growth. Take Q1, for instance: we closed on our acquisition of YourBio, which provides technology enabling consumers to draw blood without pain from the comfort of home. That will be a vital piece of our long-term strategy to bring tens of millions of subscribers onto the platform, since it eliminates friction that keeps consumers from gaining deeper health insights and unlocking a new level of preventative care. At the close of Q1, cash and short-term investments available on our balance sheet totaled $751 million. As we've said before, our main attention will be on investments that let our platform scale toward serving tens of millions of subscribers. On top of that, $225 million is left under our share repurchase program, which lets us seize moments when we think our stock's intrinsic value has meaningfully separated from its market value. Over the coming quarters, our investments will center on the strategic growth levers we laid out at the beginning of this year, which serve as the cornerstones of our 2030 financial ambitions. Those are: moving into new specialties, using technology to raise the quality of care, widening access to personalized care across specialties, leveraging partnerships so we become a best-in-class curator of health services, and growing internationally. Let me spotlight a few where we anticipate heavier investment in the near term. First, we'll keep putting money into our facilities to grow both capabilities and operating efficiency. That lays a foundation for effectively expanding into new specialties while also evolving the assortment within our current specialties. Our scale gives us the ability to keep verticalizing our existing specialties in a manner that delivers an efficiency level few in the industry can match. We plan to invest in talent as well as equipment that lays a foundation to verticalize current specialties, along with ones we might launch down the road. This lets us not only lower our cost structure, but also guarantees we can fully scale our offerings in a way that clears the high bar we set for safety and quality. Second, we believe we can raise the quality of care by eliminating friction via technology, both digital and physical. We have strong confidence that we can boost how much subscribers engage and stay with us by offering things such as blood draws done at home, chatbots powered by AI — similar to those we just started rolling out in Labs — and in time, pulling in data from wearables, which would strengthen even more the feedback cycle linking subscribers and providers. Last, going international is where we plan the biggest investment over the next several quarters. Eucalyptus, a deal we anticipate closing in the back half of this year, will substantially grow our capacity to advance the consumer experience in a number of added markets. Operating efficiently in established markets frees us to put money into strategic markets that could turn into future profit engines once they reach scale. When the Eucalyptus deal closes, we anticipate paying out roughly $240 million, with the rest of the guaranteed consideration coming as earn-out payments that run into early 2029. Because the deal's structure is flexible, we can settle a significant share of what we owe after closing using either cash or stock, which in our view underpins balance sheet flexibility over the long term. Just as we've done before, we'll keep watching the landscape for chances to strengthen our balance sheet and keep strategic options open, doing so with careful attention to dilution. Having said that, I'll go through what we expect for the rest of the year. Since we still don't know precisely when the Eucalyptus deal will close, it isn't reflected in our updated outlook; for the second quarter, we project revenue between $680 million and $700 million, which works out to a year-over-year gain of 25%-28%. We anticipate adjusted EBITDA landing somewhere from $35 million to $55 million, which equals an adjusted EBITDA margin of 7% at the midpoint of both ranges. Looking at the full year, we're lifting our 2026 revenue outlook to $2.8 billion-$3 billion, equal to a year-over-year rise of 19%-28%; we expect 2026 adjusted EBITDA to fall between $275 million and $350 million. Those adjusted EBITDA and revenue ranges suggest an adjusted EBITDA margin of 11% at the midpoint of both ranges. To give some context for our outlook, I want to call out a few things. First, as I noted earlier, our emphasis will be on sustaining robust growth. We anticipate gross margins will shrink as we put priority on scaling things like weight loss, labs, and international markets, whose gross margin profile is lower than that of the specialties we've offered longer. Those specialties give us a base for building a deeper tie with our subscribers and for becoming the top global platform for health and wellness services. Second, our track record of success has largely come from verticalizing operations so subscribers receive an outstanding level of service. We believe that produces longer tenure on the platform. Our arrangement with Novo Nordisk still lets us draw on our provider network, digital tools, and the wide range of other offerings on the platform to serve subscribers better from start to finish. One example is using our pharmacy operations to dispense drugs to members for items such as the Wegovy Pill and Wegovy Pen, which could create efficiencies down the road. For products dispensed through our pharmacies, including those originating from Novo Nordisk, we record revenue on a gross basis. We anticipate near-term pressure on margins during the second quarter, since most of our weight loss specialty is shifting to one-month supplies. We look for a significant increase in adjusted EBITDA dollars across the third and fourth quarters. As monthly cohorts brought in over the course of the year compound, we expect that to produce accelerating growth in both revenue and EBITDA. On top of that, we anticipate picking up operating leverage in G&A and continuing to realize gains in marketing efficiency. We plan to keep investing in technology across our platform. In our view, we can improve the overall consumer experience on our platform, whether through new apps and tooling, faster care, or deeper insights; we likewise hold that stronger infrastructure lets us move more quickly, and that technology can substantially lower the cost of serving consumers, whether by upgrading software to allow more efficient pharmacy operations or by finding ways to use AI to cut operational and G&A costs throughout the company. We expect that certain of these efficiency gains might begin to appear in 2027. During the first quarter, we carried out an intentional strategic shift.
We think this change, combined with how strong our other specialties are and what our platform can do, puts us in a position to turn into the go-to health and wellness provider across the U.S. We have a lot of confidence that we can repeat that success and build similar category leadership in important international markets, including Canada, the U.K., Australia, and other European countries. What we're seeing early on looks encouraging, and it gives us more conviction about where the business is headed over the long term. That path gives us the confidence to keep putting money to work and keep delivering on our mission. The opportunity ahead of us is enormous. We anticipate some ups and downs in GAAP financial margins as we keep leaning into the chance to bring more value to consumers. What we don't anticipate changing is how well we execute and how strictly we stick to our capital allocation framework, which we believe will let us produce strong free cash flow while building category leadership positions across the globe. This backs up our ongoing confidence in the 2030 ambitions we laid out last year. It'll be $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. None of our success would happen without the enormous efforts of Hims & Hers employees worldwide. I want to thank them, along with our subscribers and our shareholders, for backing us in our mission to help the world feel great through the power of better health. With that, I'll now hand the call back to Bill to start Q&A with two questions from our retail community.
Appreciate that, Yemi. And thanks to all of you who got your questions in to us across the weekend. Up first we have Chi Yung, and his question was about how we see AI fitting into the platform. Where do we want the Labs AI healthcare agent, which just launched, to go over the long haul? More to the point, what's the end goal — the final shape — that Hims & Hers is trying to get to with this product?
Yeah, thanks for asking that. We're genuinely thrilled to begin discussing a number of these AI efforts with a bit more depth. In fact, I've requested that Mo join us every quarter from here on out, and I believe that's going to be excellent. The Labs companion, along with the weight loss companion that's coming soon, represent truly the initial versions of what I anticipate will ultimately turn into numerous agents assisting at each phase of the customer journey, no matter which specialty we provide. Down the road, you'll have agents making the intake experience far more interactive and conversational. You'll have agents assisting with clinical choices and suggestions, growing better informed through resources such as MedMatch that become smarter as we expand. This makes the network effects of our worldwide consumer platform both wider and more polished. And then, I believe, you'll have continuous care and assistance that's constantly on hand, aiding you in handling various elements of your wellbeing every single day; that's a lot more sustained involvement, adherence, and clinical requirements following treatment. As Mo pointed out near the start of the prepared remarks, we're witnessing truly outstanding tech leadership coming aboard Hims & Hers, since I think they perceive what we perceive. We perceive a platform possessing enormous scale, distinctive data, infrastructure, and in the end the customer trust required to genuinely seize and capitalize on this technological breakthrough. Honestly, I think these latest rollouts represent merely the opening move in capitalizing on the stack, though in the end we intend to weave it through the whole experience so that essentially, regardless of your location on the planet, you're able to grab your phone, tap, and gain access to Hims & Hers, and in the end feel wonderful and receive the finest care imaginable, right there in your hands.
Alright, thank you. Appreciate it, Andrew. Over the weekend, a majority—above 50%—of what came in was about the growing peptide opportunity; these came both from the Hims community and from Oman, whose question was, "What's your view on the company's peptide strategy over the long term past GLP-1s, particularly regarding potential differentiation from personalized dosing, new categories, or proprietary formulas? And with that in mind, could you address what competitive edge your domestic supply chain provides here?
Well, like we said during the prepared remarks, this is a space that has us really enthusiastic — especially once you combine what this category could become with top-tier oversight from physicians and, in the end, a supply chain that's safe, since neither of those exists right now in the gray market. Taking a step back, we feel we hold a mix of assets — the brand, the infrastructure, and, in the end, the capabilities — to genuinely lead in this emerging space once the regulatory path clears up in July. To begin with, our 503A compounding footprint delivers personalization at scale. With over 1,000,000 sq ft of infrastructure at this point, we're able to back individualized dosing and formulations, sharpen cost efficiencies and margins, and, in the end, provide care that's meaningfully tailored to what each patient needs. Next, as we said during the prepared remarks, the peptide manufacturing facility we bought last year hands us a fully verticalized U.S. supply chain. By moving API manufacturing onshore, we're able to control much more of the process from start to finish, which gives us edges in quality, purity, reliability, and, in the end, brand trust, that I believe others will find extraordinarily hard to replicate, and that I think matters more and more as these treatments and therapeutics reach mass market. We've been putting money actively into our clinical experts, both internal and external, who sit kind of at the leading edge of this category. That clinical oversight, along with the clinical protocols we'll eventually put in place, should help educate patients and offer them guidance about what may be suitable under what circumstance; then, once you layer on the lab testing work we've been doing, plus the verticalization of those facilities in order to spot areas of concern and, in the end, track improvement, the whole combination strikes me as extraordinarily exciting. Given the investments we've made throughout the business over the last few years, I'm honestly not sure anyone is better positioned both to check the box on all these elements we consider absolutely critical to delivering this category safely and appropriately, and also to truly lead in the category and empower consumers with that access.
Perfect. Thank you, Andrew. Having said that, I'll hand things back over to the operator so we can kick off the usual analyst Q&A.
Hi, everyone. Good afternoon. Andrew, I had planned to ask about peptides, but I believe you addressed that fully in the previous question. Instead, maybe I'll pose two additional finance questions regarding the strategic shift. Yemi, I believe you noted there was some margin pressure as you move toward shorter shipping intervals for the branded items. Perhaps stepping back a little, could you describe what the contribution dollar profile looks like for a branded customer compared with a legacy compounded customer? That's the first question. Second question, regarding the revision to your full year revenue and EBITDA guidance, is there any method to separate how much of that stems from the weight loss strategic pivot as opposed to the remainder of the business? Thank you.
Great. Thanks for the question, Cory. Regarding what you asked, about the distinction in unit economics separating branded from compounded products, on a dollar basis, I'd say the two are approximately similar. As part of the strategic pivot, one element we have consistently maintained that we believe is essential for success from a platform standpoint is offering a wide range of assortment available to consumers; we believe that allows us to pursue an increasingly larger audience. What we observed, as we broadened the assortment on the platform, is that the count of consumers along with the demand and the traffic arriving at our platform reached levels following the launch that we truly had not witnessed since certain peak periods back in 2025. This benefits us in a few ways. First, obviously that will serve as a fairly substantial beneficiary for our weight loss specialty. Additionally, as we progressively widen the number of specialties we provide on the platform, we can attract interest toward some of those other specialties, whether as the consumer arrives or eventually, as we consider the relationship we are cultivating with consumers and the value we are delivering to our subscriber base too, possibly cross-sell them down the road. The confidence in the demand we are seeing from the site, along with sustained strength across our other specialties in the U.S., is what provided the confidence to raise the guide.
Thanks. Good afternoon, and I appreciate you taking my questions. Could you help us understand what share of your compounded GLP-1 subscribers have moved over to branded products since the Novo deal launched, and how retention has held up during that shift? Then, Andrew, I had a follow-up about peptides. If the FDA recommends reclassification in July, where do you stand on being ready to launch? Are there further investments still required? And how are you assessing the size of this opportunity internally compared with other specialties?
Thank you, Maria. Perhaps I'll begin with peptides. As I've mentioned before, and I think it bears repeating, strategically I've never felt it was essential for us to be the first entrant in any category. That will likely be particularly true for peptides. What matters most is that when we launch, we're the best in the market. Not necessarily first, but best. From our standpoint, there's a fairly lengthy list of what's required to bring that category to market safely, including clearly data transparency, supply chains validated internally, and clinical protocols that are bulletproof. Our team is hard at work on every one of those elements. We anticipate getting a better understanding by the end of July, at least regarding some of the peptides that might move to Category 1, and then potentially additional information toward the end of the year. As I put it, the team is actively getting ready on all the elements we believe would be essential for bringing that category to market; we probably won't be first, but when we do launch, we'll ensure we feel everything has been done properly. On scale and opportunity, it's difficult to estimate, though I'd say demand on both the men's and women's sides instinctively appears to be very large, correct? There's a growing emergence that the GLP-1 category likely started and provoked, which concerns patients wanting to be more proactive about health, wanting not only to address the specific issues that might be acute, but also potentially to get ahead and be more proactive about health in a far more preventative and longevity-focused way. This is showing up in many ways. For one, on the peptide side of the house, but also in categories like lab testing, which we've launched and where we're seeing great progress. The same is true for testosterone and menopause. These are far more forward-leading categories. People are beginning to take their health into their own hands and becoming empowered. My view is that this will act as a significant tailwind once emerging treatments like peptides and other longevity-focused options reach the market. Regarding the GLP versus branded question, after we made that strategic shift toward the branded side, nearly all new business now arrives on the branded side, and a large number of customers have made the switch. That is honestly how we are generating more than 100,000+ new on the volume side for Wegovy. In our view, this transition was extremely valuable. We can see that in the scale of new customers coming through the door today, which exceeds, as Yemi mentioned, any spikes we witnessed even during the biggest seasonal campaigns, including New Year's and Super Bowl campaigns. We are truly thrilled about that transition and are currently in active discussions with Novo, and I believe they feel the same enthusiasm about what they are seeing.
Great. Thank you. That's very helpful.
All right, I just have two questions about finances. Yemi, you mentioned pressure on gross margins, and I believe there are more negatives than positives, or maybe the reverse. Could you help put a number on how much lower gross margins might go as we move through this cycle from now until year-end? The EBITDA margin guidance for the second half suggests quite strong incremental margins. Could you walk through that a bit? How confident are you that you can achieve that kind of incremental margin ramp in the back half of the year? Thanks a lot.
Yes, absolutely. I appreciate the question, Mark. Let me begin with your first point about gross margin swinging around. Given the strategic pivot we've undertaken, some fluctuation in certain GAAP metrics is something we anticipate. Even so, our confidence in generating solid absolute EBITDA and robust free cash flow remains quite strong. Looking ahead across the next several quarters, I'd anticipate roughly a couple points of decline in gross margins. Even so, I'd say this is a lot like what we've seen in earlier quarters. Back then, our strategy was to build a leading position first, then use those advantages to capture economies of scale. What we're doing now follows that same game plan. At present, the company's priority is to turn itself into the go-to health and wellness provider across the United States and secure a leading spot. Down the road, that sets us up to capture larger and larger economies of scale, which lets us return value to consumers in a manner nobody else is capable of. Since our U.S. business keeps generating robust cash flow, putting that money back to work while applying our established approach in markets worldwide is essentially the mechanism we see powering things going forward. Regarding your other point about second-half EBITDA, several factors are involved. One major element we clearly observe is the shift tied to weight loss that we discussed during the prior quarter. That trend will carry on through Q2 as well. Almost everyone who signs up now picks the monthly option rather than the two-month option that used to be standard for the compounded side of the business. It's simply a matter of mechanics: once you're adding new groups every month instead of once a quarter across the year, you automatically pick up an EBITDA gain when those customers come back. On top of that, we expect the following: we put a good deal of money into G&A during the first six months. Going forward, G&A should show leverage, because we won't need to grow those costs quarter over quarter by as much. Finally, I believe we're observing this — simply the marketing efficiency we can generate quarter over quarter. We'd anticipate that to, you know, keep going as we, you know, keep finding the ability to cross-sell users effectively, keep seeing additional throughput via low acquisition channels. Finally, keep seeing stronger, you know, retention patterns. Those factors are what give us extremely strong conviction in our capacity to keep compounding EBITDA dollars across the back half of the year.
All right, thank you, Yemi.
Yeah, thanks. I've got a question about how the revenue guidance is shaping up while EBITDA is being brought down. You mentioned part of this already, but I'm also curious about some of the newer category launches — testosterone, menopause, and labs. What's your thinking there, in terms of the ramp period and when those start reaching somewhat more mature margins? That's the first thing. Second, on gross margins compressing — compared with how you previously framed it at 75% over the longer term, is there any sort of range you have in mind over a longer horizon for where the model is heading?
Yeah, thanks for the question, Craig. When it comes to taking revenue up, I'd say it mostly reflects the financial priorities we discussed a bit during the prepared remarks. We see an enormous opportunity ahead of us, in the U.S. and around the world, and we're going to keep investing so we can effectively establish a leadership position. That's because we've seen historically that when we pull that off, we can pass value back to consumers — partly by leveraging the technology Mo walked through regarding richer data sets — and we can also build an industry-leading cost structure that lets us either expand margins or return value to consumers. In the guide, taking revenue up while keeping more flexibility on EBITDA to accomplish that really reflects that priority, along with our confidence that we can capture an enormous opportunity ahead of us. As for the gross margin dynamics, I'd say that's something we'll keep providing visibility into. The company's overall financial equation hasn't changed, and that's essentially to drive strong absolute EBITDA dollars and control our own destiny with cash flow generation while establishing the leadership position we discussed.
Understood. Appreciate it.
Okay, thank you. Good afternoon. Could you talk more about the ways AI might reshape the user experience down the road, and what your thinking is around adding feedback loops? It really feels like there's a distinctive chance here to learn more about the customer and collect additional outcomes data on treatments. Second, I'd really like to hear about your strategy for wearables and whether you lean toward building your own versus partnering with companies already in that space. Thanks.
Yes, excellent questions. When it comes to AI, there are a handful of points. Like I said earlier, you can probably tell that what we're doing is essentially creating a multi-agent model in which consumers and providers alike are given power at every stage of the customer journey to optimize, personalize, and in the end produce better results for the patient. Some of that is about efficiency, though I'd argue a larger share is really about quality of care network effects, correct? There's a really strong dynamic at Hims & Hers, which is that with each patient who comes to us, we become smarter and better equipped to treat the one who follows. There's a well-known idea in healthcare around getting a second opinion, and I frequently tell my team that the models we are currently constructing and the data layer we're putting together throughout the stack ought to make it possible for any patient anywhere on earth to receive, well, 1,000 opinions simultaneously, right? Thanks to the comprehensive data from all of our, you know, nine years heading toward 10 of experience. I believe you ought to be able to get quicker replies, more tailored dosing and care recommendations. Handheld engagement experiences after the initial consultation in which you're genuinely being supported and guided through every key milestone while you stay on track with care. In the end, I believe the result of all this will simply be far greater long-term retention, considerably improved engagement rates, and probably far richer relationships with these patients. Regarding wearables, I'd say this is closely connected, right. It's another data source, much like labs, that lets us deliver the high touch care model far more effectively. I think we're weighing both routes. Both our own devices that are simple to wear, simple to charge, and able to track all the fundamentals that all of us enjoy tracking. Plus partnering with the ecosystem people already love. My overall view on this is that doing both is likely the right call. You know, we want to be universal, so that if you own particular devices you're fond of, they'll connect smoothly with the Hims & Hers experience. We'll be able to use that data, your provider will be able to use that data. Because of that relationship, we'll ultimately be able to care for you better. Beyond that, there's a dynamic I believe is quite potent — one our team is, I'd say, uniquely equipped to handle — namely, actually crafting and delivering top-tier hardware experiences. As you know, we're already doing that with YourBio, the blood testing device we offer for use at home. My sense is we can also pull this off on the device front, where, for our consumers, you're able to provide it, you know, at cost, in an extremely affordable way. Woven into various memberships and membership tiers so that your engagement and depth with the platform can simply be far richer and far more, far more powerful.
Thanks. Andrew, could you take us through the value proposition for brand manufacturers that you're presenting out there in the market, and how much you believe it will carry over past GLP-1s? Yemi, I wanted to dig deeper into what you said about the second half run rate. Would you consider that a sensible pace to annualize, or is your remark about investment meant to discourage us from annualizing it?
Yes. Thanks, Eric. That's a great question. I believe the dynamics on the branded side of the business are shifting very fast. We've gathered enough data points, whether via Novo or via firms such as GRAIL and others, and it's evident that innovative areas of pharma, biotech, devices, advanced diagnostic testing — all that innovation in the end requires distribution. I think our capacity to offer the biggest geographic footprint and the strongest consumer relationships as essentially the primary front door is a tremendously powerful element we can deliver to those partners. I believe it involves generating awareness for their category as well as driving growth for particular treatment therapies. As more products reach the market, whether in any of those areas, a huge amount of value will be directed toward our collaboration with these ecosystem partners to determine how we can get the best offerings to the right individuals. In the end, for us, trust from consumers as a curator of high-quality everyday care is our ultimate aim; achieving that demands excellent relationships with those innovating throughout the stack. I think our domestic relationship with Novo, plus our upcoming relationship with Eucalyptus and the drug companies worldwide, offers plenty of learnings about how innovators can collaborate to bring excellent products to people at scale. I believe it's speeding up many conversations occurring at this moment. There are likely 2 doz of these conversations underway, both in the US and abroad, spanning pharma, biotech, new device, and diagnostic. That's because every one of these innovators needs distribution and needs a partner who can guarantee the right customers receive access to the right care and, in the end, achieve the right outcomes. I think we can truly be a crucial partner in helping make that happen.
Addressing the second half of what you asked, Eric: because of the shift in strategy plus the weight behind it, along with a few of the wins we're getting in more recent specialty areas such as labs and testosterone, the real emphasis is on rapidly growing each of our U.S. categories so we can lock in a leading position. In earlier periods we've observed that as volume grows, our capacity to push margins upward progressively increases. Given that users are arriving on the platform at a record level, what we're concentrating on is widening share, extending reach, and growing the subscriber base as a whole; on that basis, my expectation is that revenue growth speeds up during the second half of the year. What I would anticipate when looking quarter by quarter is that spending could shift as we begin putting more behind particular opportunities where we're seeing indications of momentum. The fundamental formula we've been working from hasn't been altered and won't be altered from one quarter to the next; namely, securing a leadership spot for ourselves in order to generate economies of scale. At the same time, we need to make sure we're pursuing that while still allowing ourselves to produce solid free cash flow.
I appreciate you taking my questions, and I really value all the detail shared on this call regarding the strategic pivot. Andrew, I'm wondering — among the categories you've discussed extensively here, such as weight loss, labs, testosterone, and menopause — are these mainly U.S.-based, domestic drivers of the business right now? Or are you noticing incremental or comparable opportunities in the early phases of your international expansion, and in what you're observing through Livewell and ZAVA so far? What portion of these investments will be U.S. versus international?
Yeah, excellent question, Ryan. At present, the newer categories — you know, labs, menopause, testosterone, and so on — much of that iteration and category learning is happening domestically. I believe this playbook has historically performed very well. We've now been doing this for a few years in the U.K., where we optimize, refine, and launch here in the U.S., and then rapidly, after perhaps six to nine months, extend that to other geographic regions. When it comes to weight loss, it's somewhat of a mixed bag, since you actually have just different weight loss models. The international categories, or the international geos we've actually been operating with the branded pharmaceuticals and branded manufacturers for much longer, and we have far more tenured relationships with them. In many respects, they're already seeing that model adopted. The new categories like labs, menopause, testosterone, same things with peptides, you know, et cetera — those will begin here domestically and then quickly follow into the five or six other most critical regions.
Great, thanks. I’ll ask a quick follow-up for Yemi. Given that, when we consider the raised top-line guidance for the rest of the year, is it fair to characterize those assumptions as mainly U.S.-driven, with little from international? Thanks.
Yes. I’d say we anticipate robust expansion across the international pieces. That said, in the U.S., once certain revenue recognition dynamics we discussed are cleared, and with early indications from the strategic pivot plus new categories scaling, we do expect to see a significant step-up in the U.S. business, which we believe matters for staying aggressive on global expansion.
That wraps up the Q&A portion. Everyone, that brings us to the end of the Hims & Hers earnings call for the first quarter of 2026. We appreciate you all being with us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Hims & Hers Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Hims & Hers Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.